Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANZUW NASDAQ:DRTSW NASDAQ:HSCSW NASDAQ:NTRBW On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANZUWAnzu Special Acquisition Corp I$0.05+11.7%$0.05$0.00▼$0.15N/AN/A32,101 shs38,819 shsDRTSWAlpha Tau Medical$3.22+9.2%$1.94$0.20▼$3.22N/AN/A65,882 shs153,231 shsHSCSWHeart Test Laboratories$0.06+22.5%$0.07$0.03▼$0.18N/AN/A4,818 shs602 shsNTRBWNutriband$0.78-22.0%$1.14$0.77▼$4.50N/AN/A2,209 shs102 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANZUWAnzu Special Acquisition Corp I+0.20%+52.29%+8.03%-26.55%+41.08%DRTSWAlpha Tau Medical+9.15%+75.01%+37.02%+257.78%+1,203.64%HSCSWHeart Test Laboratories+21.54%-22.45%+21.30%-32.04%-32.71%NTRBWNutriband0.00%-13.33%+3.31%-32.17%-55.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANZUWAnzu Special Acquisition Corp I$0.05+11.7%$0.05$0.00▼$0.15N/AN/A32,101 shs38,819 shsDRTSWAlpha Tau Medical$3.22+9.2%$1.94$0.20▼$3.22N/AN/A65,882 shs153,231 shsHSCSWHeart Test Laboratories$0.06+22.5%$0.07$0.03▼$0.18N/AN/A4,818 shs602 shsNTRBWNutriband$0.78-22.0%$1.14$0.77▼$4.50N/AN/A2,209 shs102 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANZUWAnzu Special Acquisition Corp I+0.20%+52.29%+8.03%-26.55%+41.08%DRTSWAlpha Tau Medical+9.15%+75.01%+37.02%+257.78%+1,203.64%HSCSWHeart Test Laboratories+21.54%-22.45%+21.30%-32.04%-32.71%NTRBWNutriband0.00%-13.33%+3.31%-32.17%-55.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANZUWAnzu Special Acquisition Corp I 0.00N/AN/AN/ADRTSWAlpha Tau Medical 0.00N/AN/AN/AHSCSWHeart Test Laboratories 0.00N/AN/AN/ANTRBWNutriband 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANZUWAnzu Special Acquisition Corp IN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/AHSCSWHeart Test Laboratories$8.67KN/AN/AN/AN/AN/ANTRBWNutriband$1.80MN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANZUWAnzu Special Acquisition Corp IN/AN/AN/AN/AN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)HSCSWHeart Test LaboratoriesN/AN/AN/AN/AN/AN/AN/AN/A7/22/2026 (Estimated)NTRBWNutribandN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest NTRBW, DRTSW, ANZUW, and HSCSW EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/22/2026N/AHSCSWHeart Test Laboratories-$0.68N/AN/AN/A$0.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANZUWAnzu Special Acquisition Corp IN/AN/AN/AN/AN/ADRTSWAlpha Tau MedicalN/AN/AN/AN/AN/AHSCSWHeart Test LaboratoriesN/AN/AN/AN/AN/ANTRBWNutribandN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANZUWAnzu Special Acquisition Corp IN/ADRTSWAlpha Tau MedicalN/AHSCSWHeart Test LaboratoriesN/ANTRBWNutribandN/AInsider OwnershipCompanyInsider OwnershipANZUWAnzu Special Acquisition Corp IN/ADRTSWAlpha Tau MedicalN/AHSCSWHeart Test LaboratoriesN/ANTRBWNutribandN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANZUWAnzu Special Acquisition Corp I2N/AN/ANot OptionableDRTSWAlpha Tau Medical80N/AN/ANot OptionableHSCSWHeart Test Laboratories10N/AN/ANot OptionableNTRBWNutriband10N/AN/ANot OptionableNTRBW, DRTSW, ANZUW, and HSCSW HeadlinesRecent News About These CompaniesNutriband Inc to Showcase Expanding AI Wellness Product Portfolio and New June Product Launches at ECRM ConferenceMay 15, 2026 | globenewswire.comNutriband CEO, Gareth Sheridan Discusses the US Fentanyl Crisis and Company Update on Latest Episode of the Jack Neel PodcastApril 22, 2026 | globenewswire.comNutriband Selects Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchMarch 30, 2026 | globenewswire.comNutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa RicaFebruary 17, 2026 | globenewswire.comNutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion PointsJanuary 30, 2026 | globenewswire.comNutriband CEO Publishes Letter to ShareholdersDecember 31, 2025 | globenewswire.comNutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision BioDecember 29, 2025 | globenewswire.comNutriband (NASDAQ:NTRBW) Trading 0.7% Higher – Should You Buy?December 27, 2025 | defenseworld.netDNutriband Differentiates Prescription Fentanyl from Illicit Fentanyl in Response to United States Executive Order Designating Fentanyl as a Weapon of Mass DestructionDecember 18, 2025 | globenewswire.comNutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity ConferenceNovember 24, 2025 | newsfilecorp.comNREPEAT — Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl PatchOctober 28, 2025 | globenewswire.comNutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl PatchOctober 28, 2025 | globenewswire.comNutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl PatchOctober 10, 2025 | globenewswire.comNutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent TechnologyOctober 8, 2025 | globenewswire.comNutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity ConferenceOctober 8, 2025 | globenewswire.comNutriband Inc. to Present at the MicroCap Rodeo ConferenceSeptember 24, 2025 | globenewswire.comNutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA FentanylSeptember 10, 2025 | globenewswire.comNutriband Inc. announces exercise of warrants at $6.43 for Gross Proceeds of $5,306,000September 3, 2025 | globenewswire.comNutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025August 18, 2025 | gurufocus.comNutriband Inc. CEO Gareth Sheridan Takes Leave to Run for Irish Presidential Election; Serguei Melnik Appointed Interim CEOAugust 11, 2025 | quiverquant.comQMedia Sentiment Over TimeNTRBW, DRTSW, ANZUW, and HSCSW Company DescriptionsAnzu Special Acquisition Corp I NASDAQ:ANZUW$0.05 +0.01 (+11.66%) As of 06/30/2026Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices, such as auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.Alpha Tau Medical NASDAQ:DRTSW$3.11 +0.16 (+5.42%) As of 07/1/2026 04:00 PM Eastern This is a fair market value price provided by Massive. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.Heart Test Laboratories NASDAQ:HSCSW$0.06 +0.01 (+22.51%) As of 07/1/2026 10:25 AM Eastern This is a fair market value price provided by Massive. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Nutriband NASDAQ:NTRBW$0.78 -0.22 (-22.00%) As of 07/1/2026 10:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Uber’s Waymo Detour Tests the Stock’s Robotaxi Bull Case Copper Stocks Are Getting a Bigger Spotlight as Gold’s Rally Cracks AirJoule Unveils Prime System, Clearing Path to Commercialization Comcast’s NBCUniversal Split Puts Broadband Back in Focus Nike Q4 Beat Masks Core Weakness as Analysts Cut Price Targets Ouster Is Breaking Out as a Physical AI Leader: Here's What's Driving the Move Meta’s WhatsApp Shakeup Could Put India at the Center of Its Next Growth Push Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
